Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
424B4
Filing Date
Apr 30, 2015
Document Date
Apr 30, 2015
Form Description
Form of prospectus disclosing information facts events covered in both forms 424B1 424B3
Filing Group
Registration Statements
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp